Published on January 24, 2025
Creatd, Inc. (OTC: CRTD) is pleased to announce the successful completion of a strategic stock swap agreement with Enzolytics, Inc. (OTC: ENZC). This marks a significant milestone for both companies, fostering a partnership that aligns their strengths to enhance shareholder value and operational synergy. The deal includes the exchange of equity, reinforcing each company’s financial foundation while paving the way for future collaboration.
Jeremy Frommer, Chairman and CEO of Creatd, Inc. commented, “I look forward to working with the Enzolytics team to strengthen their balance sheet, improve their financials, and prepare them for a potential move to the OTCQB marketplace,” said Jeremy Frommer. “ENZC has been assigned a new CUSIP and has submitted initial documentation to FINRA for approval of a reverse split. The inherent value of this company’s immunotherapy products and antiviral treatments is at the core of this strategic relationship, but its potential can only be realized after the operating entity undergoes a complete makeover and its balance sheet is strengthened.”
Frommer expressed enthusiasm for Enzolytics’ existing pipeline and vision. “We are excited to see Harry and his team complete their mission of advancing the research they’ve started, launching new products into the market, building strategic partnerships, and expanding into international business development. The upcoming product launches, particularly the innovative food supplements with a medical focus, are a testament to the incredible work being done at Enzolytics. These milestones will not only showcase the company’s scientific and commercial potential but also position it as a leader in the biotechnology space.”
Frommer highlighted the broader role of Creatd in supporting distressed companies with strong potential. “My objective is to create a runway for success by stabilizing the business, finding new strategic investors, and ensuring that Enzolytics’ groundbreaking science takes center stage in its market. These are exactly the types of companies Creatd excels with—partnering with undervalued assets in the microcap space where the product is strong, but the operational framework needs an overhaul. Having personally experienced what it takes to survive in this market, Creatd brings the expertise to help Enzolytics unlock its full potential.”
Harry Zhabilov, Chief Science Officer and founder of Enzolytics said, “Partnering with Creatd and its exceptional leadership team allows Enzolytics to remain laser-focused on our primary objectives: advancing our groundbreaking therapeutics, establishing robust distribution channels, and ultimately saving lives. This collaboration provides the strategic support we need to accelerate our efforts, while reinforcing our commitment to delivering life-changing solutions to patients worldwide.”
About Creatd, Inc.
Creatd, Inc. is a publicly traded holding company that focuses on investments and operations across technology, media, advertising, and consumer sectors. By leveraging its expertise in structured finance and acquisitions, Creatd identifies and nurtures opportunities within small-cap companies, driving growth and innovation across its diverse portfolio.
About Enzolytics, Inc.
Enzolytics, Inc. (OTC: ENZC) is a biotechnology company focused on the research, development, and commercialization of therapeutics for infectious diseases. Its innovative products include patented therapies aimed at treating HIV, AIDS, cancer, and other conditions.
Forward Looking Statements
Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings.